Insights
Search Results
Client Highlights
8.17.26
Firm Advises Gravis Robotics on $200 Million Series A
On August 17, 2026, Gravis Robotics, a company retrofitting construction machines with autonomous technology, announced their Series A financing, with SoftBank investing $200 million in the company. The funding is the largest Series A in construction robotics history and will be used to scale autonomous machinery, bringing physical artificial intelligence (AI) directly to construction sites and embedding autonomous systems into heavy machinery fleets. Wilson Sonsini Goodrich & Rosati advised Gravis on the transaction.
Client Highlights
8.14.26
Wilson Sonsini Advises CodeRabbit on $143 Million Series C Funding
On August 12, 2026, CodeRabbit, a pioneer of AI code review, announced a $143 million Series C funding round at a $1.5 billion valuation. The round was co-led by Atomico and Smash Capital, with participation from new investors including BMW i Ventures, Datadog, Hirtle Callaghan, SineWave Ventures, and Scenic Management, and existing investors CRV, Scale Venture Partners, Flex Capital, Pelion Venture Partners, Harmony Partners, and Engineering Capital. Wilson Sonsini Goodrich & Rosati advised CodeRabbit on the transaction.
Client Highlights
8.14.26
Wilson Sonsini Advises Heaviside on $60 Million Series B
On August 12, 2026, Heaviside Industries (Heaviside), a builder of multi-domain precision munitions platforms, announced a $60 million Series B funding round, valuing the company at $600 million. Felicis led the round with participation from Hedosophia, Menlo Ventures, Cantos, Flume Ventures, Qstar Capital, Friends & Family Capital, Anorak Ventures, MVP Ventures, and others. Wilson Sonsini Goodrich & Rosati advised Heaviside on the transaction.
Client Highlights
8.13.26
Firm Advises Khartis Therapeutics on Patent Matters Related to $50 Million Series B
On August 13, 2026, Khartis Therapeutics, a biotechnology company developing both first- and best-in-class oral small molecule medicines for immunological and chronic diseases, announced that it has raised $50 million in Series B financing. The round was led by Forge Life Science Partners, with participation from Longwood Fund and Alexandria Venture Investments, alongside existing investors Foresite Capital, Lilly Asia Ventures, and Nextech Invest, bringing total capital raised to $95 million. Wilson Sonsini Goodrich & Rosati advised Khartis on patent matters related to the transaction and has served as patent counsel for the company since its inception in 2024.
Client Highlights
8.13.26
Wilson Sonsini Advises Vals AI on $40 Million Series A led by Andreessen Horowitz
On Thursday, August 13, 2026, Vals AI, an AI evaluation platform, announced the completion of a $40 million Series A financing, valuing the company at $400 million. Andreessen Horowitz led the round, with participation from existing investors 8VC, Pear VC, and Bloomberg, and new investors Hudson River Trading and NextLadder Ventures. Wilson Sonsini Goodrich & Rosati advised Vals AI on the transaction.
Client Highlights
8.12.26
Wilson Sonsini Advises Pathway on Seed Funding Round
On August 11, 2026, Pathway, a frontier lab building architectures and models that has created post-transformer models, announced additional funding at a $500 million valuation. The new capital brings the company's total seed financing to $30 million and will be used to increase compute capacity. The round included Id4 Ventures, TQ Ventures, Red Bridge Ventures, Kadmos Capital, WS Investment Co., the investment arm of Wilson Sonsini, and angel investor Jonathan Frankle, Chief AI Scientist at Databricks. Wilson Sonsini advised Pathway on the transaction.
Client Highlights
8.11.26
California Supreme Court Expands Access to Electronic Court Recording in Wilson Sonsini Litigation
On August 10, 2026, the California Supreme Court issued a unanimous opinion in Family Violence Appellate Project v. Superior Court, No. S288176, expanding access to electronic recording of trial court hearings when no court reporter is available. The court’s opinion recognized that a verbatim record of court proceedings can be essential to access to justice and that electronic recording represents an effective technology for meeting that need, particularly for indigent parties who cannot afford to hire a court reporter. The decision further expands upon access to electronic recording provided in general orders enacted by trial courts around the state.
Client Highlights
8.11.26
Firm Advises Braveheart Bio on Patent Matters Related to $382.5 Million IPO
On August 5, 2026, Braveheart Bio, a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, announced the pricing of its upsized initial public offering of 21,250,000 shares of its common stock at a public offering price of $18.00 per share. The gross proceeds from the initial public offering, before deducting underwriting discounts and commissions and other offering expenses payable by Braveheart Bio, are expected to be $382.5 million, excluding any exercise of the underwriters’ option to purchase additional shares of common stock. Wilson Sonsini Goodrich & Rosati advised Braveheart Bio on patent matters related to the transaction.
Client Highlights
8.11.26
Firm Advises Expedition Therapeutics on Patent Matters Related to $115 Million Series B
On August 5, 2026, Expedition Therapeutics, a clinical-stage biotechnology company developing novel oral small molecule therapies for inflammatory and respiratory diseases, announced the closing of an oversubscribed $115 million Series B financing led by General Atlantic, a leading global investor, with participation from RA Capital and Vivo Capital and existing investors Sofinnova Investments, Novo Holdings, Forbion, Dawn Biopharma (a platform controlled by KKR), Adage Capital Management, Balyasny Asset Management, Logos Capital, Sanofi Ventures, BVF Partners, and Venrock Healthcare Capital Partners. Wilson Sonsini Goodrich & Rosati is patent counsel to Expedition and advises the company on all patent matters, including those related to this transaction.
Client Highlights
8.11.26
Wilson Sonsini Advises Flagler Health on $50 Million Series B
On August 11, 2026, Flagler Health, which provides AI-native practice management software currently focused on musculoskeletal (MSK) care, announced the completion of a $50 million Series B funding round. Bessemer Venture Partners led the financing joined by SignalFire, Alumni Ventures, Streamlined, 186 Ventures, Proof VC, Tribeca Ventures, and Offscript. The new funding accelerates the company’s expansion across every MSK practice in the U.S. Wilson Sonsini Goodrich & Rosati advised Flagler Health on the transaction.
Client Highlights
8.07.26
Wilson Sonsini Advises Hadrian on $1.37 Billion Series D
On August 6, 2026, Hadrian, the advanced manufacturing company building highly automated factories for America, announced $1.37 billion in new equity financing to accelerate the buildout of the domestic manufacturing capacity needed to deliver America's most critical defense, aerospace, and industrial systems. The raise values Hadrian at $7.87 billion. Wilson Sonsini Goodrich & Rosati advised Hadrian on the transaction.
The financing will be co-led by WCM Investment Management, Washington Harbour Partners, Valor Equity Partners, 137 Ventures, and Baillie Gifford. JPMorganChase's Strategic Investment Group joined as anchor co-lead, investing through the firm's Security and Resiliency Initiative. The round also included major participation by 1789 Capital, as well as Morgan Stanley Wealth Management, funds managed by Apollo, accounts advised by T. Rowe Price Associates, Inc., CapitalG, Andreessen Horowitz, Founders Fund, Lux Capital, Altimeter, Construct Capital, and existing investors.
The Wilson Sonsini team that advised Hadrian on the transaction was led by partners Rezwan Pavri and Colin Conklin. The team also included:
Corporate
Jackie Jung
Andrew Lu
Nara Jo
Mary Cruz
The financing will be co-led by WCM Investment Management, Washington Harbour Partners, Valor Equity Partners, 137 Ventures, and Baillie Gifford. JPMorganChase's Strategic Investment Group joined as anchor co-lead, investing through the firm's Security and Resiliency Initiative. The round also included major participation by 1789 Capital, as well as Morgan Stanley Wealth Management, funds managed by Apollo, accounts advised by T. Rowe Price Associates, Inc., CapitalG, Andreessen Horowitz, Founders Fund, Lux Capital, Altimeter, Construct Capital, and existing investors.
The Wilson Sonsini team that advised Hadrian on the transaction was led by partners Rezwan Pavri and Colin Conklin. The team also included:
Corporate
Jackie Jung
Andrew Lu
Nara Jo
Mary Cruz
Client Highlights
8.06.26
Wilson Sonsini Advises AiDASH on $350 Million Acquisition by Schneider Electric
On July 30, 2026, Schneider Electric, a global energy technology company, announced it has entered a definitive agreement to acquire AiDASH, a cloud-native software company that provides AI-driven vegetation, asset, and climate risk intelligence to utilities and other critical infrastructure operators, in an all-cash transaction with implied enterprise value of $350 million. Wilson Sonsini Goodrich & Rosati is advising AiDASH on the transaction.